A Prospective, Double-Blind, Randomized, Placebo-Controlled Trial of AV411 [ibudilast] to Assess Its Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy in the Treatment of Neuropathic Pain
Phase of Trial: Phase I/II
Latest Information Update: 14 Jun 2016
At a glance
- Drugs Ibudilast (Primary)
- Indications Diabetic neuropathies; Neuropathic pain
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors Avigen
- 03 Nov 2007 Top-line results reported in Avigen media release.
- 24 Oct 2007 Results expected by the end of 2007.
- 15 Jun 2006 New trial record.